v3.26.1
INCOME TAXES
6 Months Ended
Jul. 03, 2026
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE G: INCOME TAXES
Tax Legislation Update
The Organisation for Economic Cooperation and Development (“OECD”) established a 15% global minimum tax applicable to multinational companies, which has been adopted by a majority of countries in which we operate and may subject us to this tax. In January 2026, the OECD issued additional guidance that is expected to reduce the global minimum tax burden on U.S. based multinationals. We are actively monitoring the legislative adoption of this guidance in relevant jurisdictions and will continue to evaluate its applicability to our operations and refine our estimates of the effective tax rate and cash tax impacts as new legislation is enacted. There was no impact on our effective tax rate in second quarter 2026.
Effective Tax Rate (“ETR”)
ETR was as follows:
 Second QuarterYear to Date
(In millions)2026202520262025
 
Income tax expense$(110)$(66)$(187)$(139)
ETR15.5 %12.6 %14.4 %14.1 %
Second quarter 2026 and 2025 ETR both benefited from favorable impacts of research and development (“R&D”) credits, tax deductions for foreign derived intangible income (“FDII”) and the favorable resolution of audit uncertainties. Second quarter 2026 ETR increased primarily due to larger second quarter 2025 favorable audit settlements, partially offset by unfavorable impacts from the Commercial Aviation Solutions (“CAS disposal group”) divestiture and establishment of a state valuation allowance for R&D credit carryforwards.
Year to date 2026 and 2025 ETR both benefited from favorable impacts of R&D credits, the favorable resolution of audit uncertainties and tax deductions for FDII. Year to date 2026 ETR benefited from the favorable impact of excess tax benefits from share based-compensation, partially offset by unfavorable return-to-provision adjustments. Year to date 2025 ETR was unfavorably impacted by the CAS disposal group divestiture and a state legislative change that required us to establish a valuation allowance on R&D credit carryforwards.